UNIVERSAL HEALTH REALTY INCOME TRUST REPORTS FINANCIAL RESULTS FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2026

Universal Health Realty Income Trust reported Q3 2026 net income of $4.9 million, or $0.35 per diluted share, up from $4.0 million and $0.29 a year earlier; FFO rose to $12.3 million from $12.2 million, with FFO per share unchanged at $0.88. Nine-month adjusted net income increased to $15.1 million ($1.09 per diluted share), while FFO reached $37.1 million ($2.67 per diluted share), up from $35.9 million ($2.59). The trust paid a $0.75-per-share Q3 dividend and said an October Chicago land sale for $1.96 million net proceeds is expected to generate a roughly $1.90 million gain in Q4.

Analysis

The reported EPS improvement overstates the change in recurring economics: much of the quarterly comparison reflects prior-year depreciation, while diluted FFO per share was unchanged. The cleaner signal is modest nine-month FFO growth, helped by lower borrowing costs; that benefit is less durable if rates reset higher or incremental borrowing funds assets that do not promptly contribute. The October land sale can lift fourth-quarter GAAP earnings but is not an operating-growth catalyst and should not support a higher recurring-earnings multiple.

The main upside is the new medical office building: completion and lease commencement could add a visible rent stream, but the UHS master lease is reducible as third-party tenants sign. Underwrite the 75% coverage as a backstop, not guaranteed long-term occupancy; verify final project cost, rent terms, third-party leasing and funding. UHS affiliation also creates tenant-concentration and related-party exposure, so property growth is not fully independent diversification.

Near term, the land gain may make headline earnings look stronger than FFO. Over 1–3 months, monitor building delivery and any financing disclosure; over 6–18 months, the test is whether FFO growth outpaces dividend growth without materially increasing leverage. The credit facility is substantially drawn and matures in 2028, leaving rate/refinancing sensitivity relevant despite current borrowing-cost relief. The thesis weakens if FFO per share declines toward or below the quarterly dividend, the building is delayed or underleased, or borrowing costs rise. No valuation or market-price context is supplied, so the release alone does not justify a directional trade.

Key Decisions for Investors

• Do not chase the GAAP earnings increase as evidence of accelerating operations; for new exposure, wait for price and valuation context plus confirmation that recurring FFO is growing.
• Existing income-oriented holders can monitor rather than trade the release: quarterly FFO per share currently exceeds the dividend, but FFO is not cash flow, so verify operating cash flow, recurring capital needs and distribution coverage before treating the payout as secure.
• Set a catalyst alert for the medical office building’s expected December completion. Reassess only after confirming total cost, lease commencement, UHS rent obligations and third-party leasing; treat slippage, lower master-lease coverage or a higher project cost as negative.
• Track facility utilization, effective borrowing rate and refinancing plans into the 2028 maturity. A renewed rise in interest expense or FFO per share approaching the dividend would falsify the modestly constructive income thesis.